Market Spotlight
Moderna After the Cancer Vaccine Data: What Has to Be True
A first-in-class Phase 3 win added about USD 32bn to Moderna in three sessions. The cash line, guided lower by year end, is the factor nobody discussed.
Jack Green·22 Aug 2026